DLHC - NASDAQ
DLH Holdings Corp.
DLHC·NASDAQ
$5.51
-1.6%IndustrialsSpecialty Business Services
DLH Holdings Corp. provides technology-enabled business process outsourcing, program management solutions, and public health research and analytics services in the United States. The company offers defense and veterans' health solutions, including healthcare, technology, and logistics solutions to the VA, Defense Health Agency, Tele-medicine and Advanced Technology Research Center, Navy Bureau of Medicine and Surgery, and the Army Medical Research and Material Command. It also provides a range of human services and solutions, which consists of monitoring and evaluation, electronic medical records migration, data collection and management, and nutritional and social health assessments; and IT system architecture design, migration plan, and ongoing maintenance services. In addition, the company offers public health and life sciences services, such as clinical trials, epidemiology studies, and disease prevention; and health promotion to underserved and at-risk communities through development of strategic communication campaigns, research on emerging trends, health informatics analyses, and application of best practices. It primarily serves the federal health services market. The company was formerly known as TeamStaff, Inc. and changed its name to DLH Holdings Corp. in June 2012. DLH Holdings Corp. was incorporated in 1969 and is headquartered in Atlanta, Georgia.
At a Glance
Live SnapshotMarket Cap$79.86M
EPS0.0947
P/E Ratio58.18
Earnings Date08/05/2026
Earnings Call Transcript
DLHC • 2026 • Q2
Operator
Good day, and welcome to the DLH Holdings Fiscal 2026 second quarter earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Chris Witty, investor relations advisor. Please go ahead, Chris.
Chris Witty
Thank you. Good morning, everyone. On the call with me today is
Chris Witty
On today's call, we will be referencing both GAAP and non-GAAP financial measures. A reconciliation of our non-GAAP results to our reported GAAP results is included in our earnings release and in the investor presentation on DLH's website. President and CEO
Zach Parker
Thank you, Chris, and good morning, everyone. Welcome to our second quarter conference call. I am pleased for the opportunity to report our financial results and provide color regarding the current environment and our outlook. As I begin, I would like to recognize the performance of our highly skilled workforce. Our people are our number one asset as a company, and we lean on the passion, creativity, and expertise of our staff in order to succeed. This past quarter, you once again demonstrated the innovative thinking required to support our customers' critical missions and delivered excellence across the way. We continue to thank everyone at DLH for this execution. Now, turning to slide four, I'll provide an overview of the federal marketplace achievements and financial performance. The fiscal 2026 budget cycle is now complete, and the 2027 outlook is coming into focus.
Zach Parker
We believe that the current federal funding environment is favorable to DLH. Clients across our markets have increased funding capacity and improved budget visibility, allowing for a steadily improving procurement environment. Key federal health agencies received FY 2026 funding increases compared to the FY 2025 levels, reversing in part the previously proposed funding reductions outlined by the president's request for fiscal 2026. Agencies in the defense and intelligence market have received significant budget increases that align particularly well with our capabilities. These are supported on both sides of the aisle, and we expect to be a healthy profile for us in the years to come. We believe that the improved clarity and stability, which has emerged in the recent months, meaningfully expands the company's addressable market and supports the company's strategic organic growth initiatives.
Zach Parker
Last year, and throughout the shutdown in our FY fiscal year Q1, budget uncertainty and large reductions to the federal agency contracting departments significantly slowed procurement activity across the government. Such, numerous key deals and strategic large procurements that we were expecting in FY 2025 are just now coming up for bid. We are encouraged by the increase in bidding activities and are experiencing a busy second half of the fiscal year responding to procurement requests. We expect certain award decisions over the coming months, subject to customer timelines and the procurement processes. DLH continues to maintain a healthy pipeline of opportunities which will leverage our world-class workforce, our advanced capabilities, and our recently developed commercial technology differentiators to elevate our win probabilities in this pipeline.
Zach Parker
Notably, the President's recently released fiscal 2027 budget request calls for historic spending increases in the defense and intelligence sector. The administration proposes that this investment be partially offset by unspecified reductions in federal health spending. As always, the President's budget request is an initial step in the multi-phase federal budget cycle. We will remain engaged with the Hill, our customers, and influential industry groups as this process advances. Additionally, the current administration has taken several actions intended to simplify contracting and to accelerate the time required to complete transactions. We find this is very healthy for our industry.
Zach Parker
In addition to non-traditional contract arrangements that we discussed at our recent shareholder meeting. There have been executive orders to streamline the regulatory environment in contracting and to rebalance the risk-reward trade-off, moving away from some of their cost reimbursement contracts to fixed price arrangements with performance metrics. The changes align very well with DLH's strategy and our heritage. We welcome this needed shift by our government. Our defense and intelligence customers continue to prioritize prototyping, rapid delivery, cost efficiency, digital modernization, and the integration of advanced technologies, particularly as they relate to health and C4ISR systems. These align very well with our DLH Cyclone and DLH Nexus Labs, digital sandbox investments that are cloud secure. In parallel, federal health agencies remain focused on interoperability, cybersecurity, including zero trust architectures, cloud migration, and AI adoption.
Zach Parker
Collectively, these priorities position DLH very strong to grow organically from these initiatives. It is always gratifying when DLH innovation and performance excellence is acknowledged by our industry. In recent months, DLH supported projects in automation, artificial intelligence, scientific research, data science, and information technology were recognized by customer and industry organizations for outstanding program performance and significant technology achievements. We are proud of these accomplishments as they illustrate the thought leadership, ingenuity, and passion of our employees in advancing the missions of our customers. While revenue was down year-over-year, largely due to the previously discussed program transitions to small business set-aside contracts, these include the VA CMOP and Head Start, we remain committed to maximizing shareholder value. Through strong project management delivered margins and implemented cost-scaling initiatives, we delivered an adjusted EBITDA margin of 9.0%.
Zach Parker
As Kathryn will discuss in more detail shortly, we continue to de-lever our commitment to the balance sheet. Total debt was reduced to $132.7 million, aligned with our debt reduction plans for FY 2026. In late-breaking news, we were awarded a two-year sole source extension of one of our contracts to provide world-class clinical research support services to the National Institutes of Health. We truly appreciate the opportunity to continue this tremendous support in this critical public health mission that has been a primary focus area for DLH for decades. Overall, we remain well-positioned to succeed over the coming years and are excited to vie for the high-value organic growth opportunities that our company was assembled to compete for.
Zach Parker
Our differentiated suite of data science and AI/ML technology applications, our outstanding capabilities, and workforce aligns exceptionally well to position us for work within our three strategic pillars: science, research, and development, digital transformation and cybersecurity, and systems engineering and integration. As government acquisition strategies evolve, we remain prepared and proactive, leveraging speed, innovation, and agility to compete on multiple fronts in an accelerated acquisition landscape. With that, I'd now like to turn the call over to our Chief Financial Officer, Kathryn JohnBull. Kathryn?
Kathryn JohnBull
Thank you,
Kathryn JohnBull
We reported adjusted EBITDA of $5.3 million for the quarter, compared to $9.4 million in the prior year period, with the decrease primarily driven by the change in revenue volumes. Adjusted EBITDA margin was 9% for the quarter, adjusting for the timing and incremental cost impact of our cost-scaling initiatives implemented in the second quarter. From a free cash flow standpoint, we generated approximately $3.8 million during the quarter. In comparison to the prior year period, the prior year reflects the results of significant working capital build stemming from the transition of a CMOP location that restricted cash collections early in fiscal 2025. Now turning to slide seven. I'll wrap up with a summary of our debt reduction efforts, which remain a key focus area for DLH.
Kathryn JohnBull
Debt reduced during the quarter to $132.7 million, a reduction from $136.6 million at the end of the previous quarter. This marks the resumption of our deleveraging trend after the typical seasonal uptick we experienced in the first quarter. We expect to convert approximately 50%-55% of EBITDA generated during FY 2026 to reduce debt by year-end. We remain well ahead of our mandatory repayment schedule and in full compliance with all financial covenants. With that, I would now like to turn the call over to our operator to open up for questions.
Operator
We will now begin the question-and-answer session. To ask a question you may press star then one on your telephone keypad. If you're using a speaker phone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question please press star then two. At this time, we will pause momentarily to assemble our roster Our first question comes from Joe Gomes with Noble Capital.
Joe Gomes
Good morning.
Kathryn JohnBull
Good morning, Joe.
Zach Parker
Hey, good morning, Joe.
Joe Gomes
I just want to start out on the VA CMOP. You know, do we have anything left there? You know, how much longer do you think that's gonna run through? I know we were hoping it would end, I think, in this, the fiscal third quarter of this year, but maybe a little just update on where we stand on that.
Zach Parker
Yeah, I think we're still on plan, with regard to that reduction. You know, the VA and our team have been working collaboratively towards standing down the final couple operations. Kathryn, do you have any greater specificity for that?
Kathryn JohnBull
Sure, yes. Our expectation is that we will wrap up the transition of those contracts just before Memorial Day.
Joe Gomes
Okay. Get that behind us.
Kathryn JohnBull
Yes, sir.
Zach Parker
Yeah. It's obviously it served us well. You know, we remain committed, Joe, to supporting our nation's veterans. We've got, we've still got irons in the fire for transitioning to different types of work for the VA. Once again, once the VA changed that acquisition process, not only to small business set-aside, but changed it from, you know, from being a solutions and tech-derived execution to just butts in seats. We withdrew all of our joint venture bids and, you know, approached it accordingly. It's bittersweet. As you know, we had a couple of decades of support in that arena, but we wish the small business community well.
Joe Gomes
Right. Exactly. Agreed. You know,
Joe Gomes
If you might be able to provide us a little more color on that, the nice late-breaking news of the new award that you re-received.
Zach Parker
You bet, Joe. First of all, on the, I'll cover the market, what we see in the market, and I'll ask Kathryn to address the extensions. Yeah, we, you know, we're always very mindful of what the headwinds could be as we have, you know, we've come to know continuing resolutions and shutdown risk quite well over the years, recent years and certainly with this administration. We're also encouraged by some multi-year funding initiatives that have gone forward that have already been approved that we anticipate continuing to move forward in selected agencies.
Zach Parker
Particularly, we still find good strength and support on both sides for defense and intelligence budgets as well as critical healthcare programs. We're really pretty comfortable in that arena. More importantly, Joe, in the last quarter, we have seen actually multiple RFPs that we have been signaling were coming. Fortunately, these have gotten under the wire before the September crisis, the usual September crisis. I think that was also attributed to some of the budget visibility. Once they got the budget passed, customers have had some pent-up demands for moving along on some of these procurements.
Zach Parker
We think that the fact that we've had three or four of the more material ones come through already. We have submitted bids. We're hopeful that the decision process will also move forward in the coming quarter. Often for very material bids, it's often they see a protest or something of that nature that might delay the actual award and start of work. We believe that we've got, you know, some that we're very well positioned, that, you know, we should have decisions by this fiscal year. With regard to the contract extensions, Kathryn, over to you.
Kathryn JohnBull
Sure, yeah. It is as we mentioned, it's the continuation of a key contract we've been working in support of the NIH for a number of decades. It would have gone through a normal recompete cycle at the completion of its 10-year period of performance here shortly. The NIH has decided to or made the case to extend it for under a sole source bridge for two years. Anytime, of course, an important part of your portfolio gets an extension and gives you additional revenue visibility, that's always very welcomed.
Kathryn JohnBull
That's work that's really reflects, as
Joe Gomes
Okay. Thank you for that color. On the, you know, the cost scaling or the right sizing, are we where we need to be, you know, for the current or the expected near-term revenue production? Do you think there might even be more cost scaling that needs to occur here?
Kathryn JohnBull
I think we've done the significant actions. We always have some strategies we're working through, and those would continue to be as leases come due, for example, continuing to evaluate our footprint in our real estate, those kind of activities. We continue to evaluate and assure that our cost structure remains competitive and allows our rates to stay competitive for bidding on new work. We think that we've accomplished the material reductions that are necessary to right-size the business.
Joe Gomes
Okay, great. Thanks. I'll get back in queue.
Zach Parker
You bet. Thank you, Joe.
Kathryn JohnBull
Thanks, Joe.
Operator
If you have a question, please press star then one.
Zach Parker
Hearing none, do we wanna reopen it for Joe? Operator?
Operator
He is not back in the queue. Joe, if you need to re-queue.
Zach Parker
Okay. Just give Joe just a second as he did put himself back in the queue, and if not, we'll move forward. All righty. Well, with that, I'd like to thank everyone for your participation throughout this call today.
Operator
Joe Gomes is on the call.
Zach Parker
Okay. Joe, anything else?
Joe Gomes
Yeah, maybe a little more. You know,
Zach Parker
Yes.
Joe Gomes
what we've seen here in the past couple of years, you know, it's been a challenging time for DLH in losing, you know, obviously the.
Zach Parker
Yeah.
Joe Gomes
CMOP business and the Head Start and, you know, to potentially see prioritizing federal health spending, you know, it just throws up, you know, additional challenges for the company.
Zach Parker
Yeah.
Joe Gomes
Maybe you can give us a little more your thoughts and color and how you're gonna go about this, you know, addressing this.
Zach Parker
You bet. You bet. No, great question again, Joe. Yeah, I think, you know, the best way we characterize it is, as you well know, we advertise, communicate it, try to be very transparent with regard to what, you know, largely was fueled by the Biden administration's commitment to move not only the VA, but a number of other agencies' contracts to small business. We anticipated that erosion. It started in 2024 and certainly matured in 2025. As you indicated earlier, we expect to have the final pieces of the headline set aside for us, which was VA CMOP, finally running out this year.
Zach Parker
But having said that, we're also well-positioned, and we're very optimistic that the RFPs and solicitations that had been earmarked for FY 2024 align with our, you know, establishment of our differentiators in data science and data analytics. We're gonna be fueled by RFPs in FY 2025. Unfortunately, as we indicated earlier, it was all of those basically stalled. Not all of them, but the overwhelming majority of those are basically stalled. So we had a relatively flat bid cycles for the major new business deals that are just now coming around. A few of those have evolved from the government deciding to move towards some grants.
Zach Parker
The DOGE effect, certainly impacted a lot of our clients where they did not have the acquisition officials to issue those RFPs. They've begun to stabilize that over the course of the last six months. And again, we're starting to see both in the defense and intel side and in the public health arena, those solicitations come back. We've got a few we're anticipating in the next few months. We've got a pretty healthy revenue potential for some that have recently submitted. So we're just optimistic that that trend will continue. We're not expecting to have a series of the major DOGE government cuts, major DOGE program cuts, budget cuts, followed by, you know, historical shutdowns in the coming months.
Zach Parker
The global challenges, both including the war in the Gulf, are going to certainly keep a strong commitment of funding and rapid development initiatives for the defense and defense health arena as well. We right now do see good optimism, you know, that the flatness in terms of opportunities for us to compete in 2025 is starting to break, and that's good for us. What we thought was going to be a pretty quick V curve turned out to become a little more bathtub. We are starting to see the opportunities hit now and certainly feel that we'll be able to compete favorably for our share.
Joe Gomes
Thanks for that color,
Zach Parker
We can't wait. Yeah.
Kathryn JohnBull
100%.
Zach Parker
Yes.
Operator
This concludes our question-and-answer session. I would like to turn the conference back over to
Zach Parker
Well, again, I want to thank you all for, again, your participation, your interest in DLH. We remain committed to driving that shareholder value. We are looking forward to chatting with you with in the coming quarters. We ask everyone have a blessed day, and we'll talk again soon. Bye for now.
Transcript from May 7, 2026
Other Transcripts
Related Guides
Continue your DLHC research with focused valuation guides.
Research Paths
1
Snapshot
Start with context, operating signals, and key market metrics.
2
Value Model
Stress test fair value across bear, base, and bull assumptions.
3
Statements
Validate revenue quality, margins, and balance sheet durability.
4
Earnings Call
Read management commentary and compare it with reported outcomes.
5
Dividends
Check payout sustainability and long-term distribution behavior.
6
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.